Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PsiloStudy
NCT06853912Phase 2Active, not recruiting
- Start
- Jun 2025
- Primary completion
- Nov 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD) comparing Psilocybin + Nondirective Psychological Support with Placebo + Nondirective Psychological Support (2 arms). Primary endpoint: Safety of Psi-PS at 1 week. Started Jun 2025; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
alcohol use disorder (AUD)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT06853912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06853912.